2020
DOI: 10.1016/j.clml.2020.02.015
|View full text |Cite
|
Sign up to set email alerts
|

Real-world Experience of Imatinib in Pediatric Chronic Phase Chronic Myeloid Leukemia: A Single-center Experience From India

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

2
6
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(9 citation statements)
references
References 40 publications
2
6
1
Order By: Relevance
“…Similar to our experience, 20% of children presented with advanced disease in a study by Ganguly et al from another major cancer hospital in India. 22 A study from Japan reported that around 10% (23/238) of children with CML (including both chronic and advanced phases) had clinical leucostasis in their patients, which was twice as common compared to our study (5.7%). Furthermore, ocular symptoms were the most frequently observed (14/238) symptom in the Japanese study, followed by priapism (4/238), whereas pulmonary leucostasis was more common in our cohort.…”
Section: Discussioncontrasting
confidence: 54%
See 1 more Smart Citation
“…Similar to our experience, 20% of children presented with advanced disease in a study by Ganguly et al from another major cancer hospital in India. 22 A study from Japan reported that around 10% (23/238) of children with CML (including both chronic and advanced phases) had clinical leucostasis in their patients, which was twice as common compared to our study (5.7%). Furthermore, ocular symptoms were the most frequently observed (14/238) symptom in the Japanese study, followed by priapism (4/238), whereas pulmonary leucostasis was more common in our cohort.…”
Section: Discussioncontrasting
confidence: 54%
“…23 The mean (SD) time to CCyR and MMR in our cohort was significantly delayed when compared to the milestones suggested in the modified ELN/NCCN guidelines. Data from the published literature 11,[19][20][21][22] on cytogenetic and molecular response in children are quite varied (Table 4). Despite the delay in response to imatinib, only three patients in the entire cohort had progressed to BC and excellent EFS and OS were observed in this cohort similar to other studies from India.…”
Section: Discussionmentioning
confidence: 99%
“…There is a 35% gap between EFS and OS in our study, which is comparable to the observation of a 28% gap in another report (5-year EFS and OS: 64% and 92% respectively). 20 This gap highlights the fact that many patients with suboptimal responses to imatinib continue to respond for a prolonged time and the lower EFS is mostly due to noncompliance to treatment in our study. More recently, the availability of second-generation TKIs like nilotinib and dasatinib can be prescribed to those who fail imatinib.…”
Section: Discussionmentioning
confidence: 78%
“…In a report from Delhi, 3% and 17% of patients had a diagnosis of AP and BC respectively. 20 Reports from developed countries indicate that 2-6% of children present in AP and 2-4% BC. 6,21 CML in children is different compared with adults ($2% AP and 1% BC), as a higher proportion present in AP and BC.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation